retatrutide news today recency 3 mounjaro tirzepatide (tirzepatide), now approved for weight loss! As a physician this Today, we shared new data

Rather than viewing glucagon as a metabolic enemy, researchers now recognize that balancing its effects alongside GLP-1 and GIP may unlock a new generation of diabetes and obesity treatments

Pregnancy and breastfeeding : Retatrutide is not recommended during pregnancy or breastfeeding, as its safety in these situations has not been established

Key topics include the significant shortages of GLP-1 drugs like Wegovy, Zepbound, and Ozempic, the rise of drug compounding as a response to these shortages, regulatory challenges and safety concerns with compounded GLP-1 drugs, and more

Several evidence-based strategies can significantly reduce bruising risk when administering semaglutide injections

A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes